Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals
I'm PortAI, I can summarize articles.
Analyst Gil Blum from Needham reiterated a Buy rating for Recursion Pharmaceuticals, citing promising clinical study results and an upcoming FDA meeting. The Phase Ib/2 TUPELO study showed 75% of patients experienced a reduction in polyps, indicating potential success for REC-4881. The treatment's durability and manageable toxicities further support the Buy rating. Blum, a 4-star analyst, has a $8.00 price target for the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments